This is a StreetInsider.com Premium Only Page

Curis (CRIS) – StreetInsider.com Reports

Feb 9, 2024 06:35 AM Curis (CRIS) PT Lowered to $26 at H.C. Wainwright

Feb 8, 2024 04:31 PM Curis (CRIS) Files for Up to $300M Share Offering

Feb 8, 2024 08:08 AM Curis (CRIS) Misses Q4 EPS by 203c

Feb 8, 2024 08:04 AM Curis (CRIS) Issues Q4 Update

Dec 12, 2023 08:11 AM Curis (CRIS) Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Dec 5, 2023 08:07 AM Curis (CRIS) Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

Nov 16, 2023 04:23 PM Truist Securities Starts Curis (CRIS) at Buy; 'The next Pharmacyclics'

Nov 2, 2023 08:29 AM Curis (CRIS) Tops Q3 EPS by 19c

Nov 2, 2023 08:02 AM Curis (CRIS) Issues Q3 Business Update

Aug 3, 2023 04:25 PM Curis (CRIS) Reports In-Line Q2 EPS

Jul 6, 2023 08:02 AM Curis (CRIS) Announces FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

Jul 6, 2023 08:01 AM Curis (CRIS) Prices 18.4M Share Offering at $0.82/sh

May 4, 2023 04:47 PM Curis (CRIS) Reports In-Line Q1 EPS

Dec 12, 2022 10:02 AM Curis (CRIS) Halted on LUPD

Dec 12, 2022 10:01 AM Curis (CRIS) Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Nov 10, 2022 06:49 AM Curis (CRIS) PT Lowered to $9 at H.C. Wainwright

Nov 9, 2022 04:04 PM Curis (CRIS) Tops Q3 EPS by 3c

Aug 30, 2022 08:01 AM Curis (CRIS) Announces FDA Lifted Hold on Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study CRIS: Curis

Aug 18, 2022 10:36 AM Curis (CRIS) call put ratio 142 calls to 1 put with focus on August 2.5 calls

Aug 18, 2022 08:16 AM Curis (CRIS) Climbs 30% After FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

Aug 18, 2022 08:01 AM Curis (CRIS) Announces FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

Aug 2, 2022 05:53 AM Stocks with Implied Volatility Movement

Jun 6, 2022 06:32 AM H.C. Wainwright Reiterates Buy Rating on Curis (CRIS), Comments on Weekend Update

Jun 6, 2022 06:26 AM Curis (CRIS) Shares Surge 25%, Laidlaw Comments, Reiterates Buy and $22 PT

Jun 6, 2022 06:15 AM Curis (CRIS) Climbs 28% Premarket

Jun 4, 2022 01:43 PM Curis (CRIS) Reports Encouraging Emavusertib Data

May 31, 2022 04:25 AM Stocks with Implied Volatility Movement

May 18, 2022 04:28 AM Stocks with Implied Volatility Movement

Apr 11, 2022 08:03 AM Curis (CRIS) Announces FDA Partial Clinical Hold for TakeAim ymphoma Study of Emavusertib

Apr 5, 2022 08:00 AM Curis (CRIS) PT Lowered to $10 at B.Riley

Apr 4, 2022 11:29 AM UPDATE: Raymond James Downgrades Curis (CRIS) to Market Perform

Apr 4, 2022 07:02 AM Curis (CRIS) Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib

Mar 7, 2022 11:04 AM Curis (CRIS) Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Feb 24, 2022 05:22 PM Curis (CRIS) Misses Q4 EPS by 2c

Jan 6, 2022 07:08 AM Curis (CRIS) Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS

Dec 6, 2021 08:03 AM Curis (CRIS) Appoints John A. Hohneker to its Board

Nov 10, 2021 10:06 AM Increasing unusual option volume: ADT NLS CRIS POSH WEN AUR API

Oct 13, 2021 06:24 AM UPDATE: Raymond James Starts Curis (CRIS) at Outperform

Oct 7, 2021 09:02 AM Curis (CRIS) Announces New Preclinical Data Highlighting Potential of CA-4948 in Multiple Hematologic Malignancies Presented at the AACR-NCI-EORTC Virtual Conference

Aug 3, 2021 04:39 PM Curis (CRIS) Misses Q2 EPS by 1c

Jul 29, 2021 06:46 AM Companies with NDRs 7/29

Jul 27, 2021 06:34 AM Companies with NDRs 7/27

Jun 25, 2021 08:02 AM Curis (CRIS) to Join Russell 2000®, 3000® and Microcap® Indexes

Jun 11, 2021 08:09 AM Curis (CRIS) Falls 18% Following Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with R/R AML and MDS

Jun 11, 2021 07:03 AM Curis (CRIS) Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with R/R AML and MDS

Jun 11, 2021 03:18 AM Curis (CRIS) 30-day option implied volatility at 189

May 12, 2021 04:04 PM Curis (CRIS) Misses Q1 EPS by 2c

May 12, 2021 11:22 AM Curis (CRIS) Extends Gain, Up 75%

May 12, 2021 11:00 AM Curis (CRIS) Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Association 2021 Virtual Congress

May 12, 2021 10:58 AM Curis (CRIS) Halted on LUDP, Up 11%